215 related articles for article (PubMed ID: 33544320)
1. Diagnostic value of [
Jamsek J; Hocevar M; Bergant D; Zaletel K; Rep S; Lezaic L
Ann Nucl Med; 2021 Apr; 35(4):429-437. PubMed ID: 33544320
[TBL] [Abstract][Full Text] [Related]
2. More advantages in detecting bone and soft tissue metastases from prostate cancer using
Pianou NK; Stavrou PZ; Vlontzou E; Rondogianni P; Exarhos DN; Datseris IE
Hell J Nucl Med; 2019; 22(1):6-9. PubMed ID: 30843003
[TBL] [Abstract][Full Text] [Related]
3. Medullary Thyroid Carcinoma: Do Ultrasonography and F-DOPA-PET-CT Influence the Initial Surgical Strategy?
Brammen L; Niederle MB; Riss P; Scheuba C; Selberherr A; Karanikas G; Bodner G; Koperek O; Niederle B
Ann Surg Oncol; 2018 Dec; 25(13):3919-3927. PubMed ID: 30306375
[TBL] [Abstract][Full Text] [Related]
4. F-18-Dopa Positron Emission Tomography/Computed Tomography Is More Sensitive Than Whole-Body Magnetic Resonance Imaging for the Localization of Persistent/Recurrent Disease of Medullary Thyroid Cancer Patients.
Terroir M; Caramella C; Borget I; Bidault S; Dromain C; El Farsaoui K; Deandreis D; Grimaldi S; Lumbroso J; Berdelou A; Hadoux J; Hescot S; Hartl D; Baudin E; Schlumberger M; Leboulleux S
Thyroid; 2019 Oct; 29(10):1457-1464. PubMed ID: 31530235
[No Abstract] [Full Text] [Related]
5. Impact of ¹⁸F-FDG PET/CT for detecting recurrence of medullary thyroid carcinoma.
Ozkan E; Soydal C; Kucuk ON; Ibis E; Erbay G
Nucl Med Commun; 2011 Dec; 32(12):1162-8. PubMed ID: 21946617
[TBL] [Abstract][Full Text] [Related]
6. Diagnostic utility of PET/CT with
Romero-Lluch AR; Cuenca-Cuenca JI; Guerrero-Vázquez R; Martínez-Ortega AJ; Tirado-Hospital JL; Borrego-Dorado I; Navarro-González E
Eur J Nucl Med Mol Imaging; 2017 Nov; 44(12):2004-2013. PubMed ID: 28646462
[TBL] [Abstract][Full Text] [Related]
7. (18)F-DOPA PET/CT in the diagnosis and localization of persistent medullary thyroid carcinoma.
Archier A; Heimburger C; Guerin C; Morange I; Palazzo FF; Henry JF; Schneegans O; Mundler O; Abdullah AE; Sebag F; Imperiale A; Taïeb D
Eur J Nucl Med Mol Imaging; 2016 Jun; 43(6):1027-33. PubMed ID: 26497699
[TBL] [Abstract][Full Text] [Related]
8. [
Rasul S; Hartenbach S; Rebhan K; Göllner A; Karanikas G; Mayerhoefer M; Mazal P; Hacker M; Hartenbach M
Eur J Nucl Med Mol Imaging; 2018 Nov; 45(12):2159-2169. PubMed ID: 29766245
[TBL] [Abstract][Full Text] [Related]
9.
Beheshti M; Hehenwarter L; Paymani Z; Rendl G; Imamovic L; Rettenbacher R; Tsybrovskyy O; Langsteger W; Pirich C
Eur J Nucl Med Mol Imaging; 2018 Sep; 45(10):1762-1771. PubMed ID: 29516131
[TBL] [Abstract][Full Text] [Related]
10. Clinical impact of
Tuncel M; Kılıçkap S; Süslü N
Ann Nucl Med; 2020 Sep; 34(9):663-674. PubMed ID: 32602032
[TBL] [Abstract][Full Text] [Related]
11. Prospective study on the clinical relevance of
Califano I; Pitoia F; Chirico R; De Salazar A; Bastianello MJ
Endocrine; 2022 Jun; 77(1):143-150. PubMed ID: 35489000
[TBL] [Abstract][Full Text] [Related]
12.
Ciappuccini R; Licaj I; Lasne-Cardon A; Babin E; de Raucourt D; Blanchard D; Bastit V; Saguet-Rysanek V; Lequesne J; Peyronnet D; Grellard JM; Clarisse B; Bardet S
Thyroid; 2021 May; 31(5):800-809. PubMed ID: 33183159
[No Abstract] [Full Text] [Related]
13. The role of
Şahin OE; Uslu-Beşli L; Asa S; Sağer S; Sönmezoğlu K
Hell J Nucl Med; 2020; 23(3):321-329. PubMed ID: 33367304
[TBL] [Abstract][Full Text] [Related]
14. THE COMBINED USE OF CALCITONIN DOUBLING TIME AND
Yang JH; Camacho CP; Lindsey SC; Valente FOF; Andreoni DM; Yamaga LY; Wagner J; Biscolla RPM; Maciel RMB
Endocr Pract; 2017 Aug; 23(8):942-948. PubMed ID: 28614009
[TBL] [Abstract][Full Text] [Related]
15. Diagnostic Accuracy of 18F-FDG PET/CT in Patients With Biochemical Evidence of Recurrent, Residual, or Metastatic Medullary Thyroid Carcinoma.
Rodríguez-Bel L; Sabaté-Llobera A; Rossi-Seoane S; Reynés-Llompart G; Vercher Conejero JL; Cos-Domingo M; Moreno-Llorente P; Pérez-Maraver M; Cortés-Romera M; Gámez Cenzano C
Clin Nucl Med; 2019 Mar; 44(3):194-200. PubMed ID: 30562193
[TBL] [Abstract][Full Text] [Related]
16. Predictive and prognostic value of 18F-DOPA PET/CT in patients affected by recurrent medullary carcinoma of the thyroid.
Caobelli F; Chiaravalloti A; Evangelista L; Saladini G; Schillaci O; Vadrucci M; Scalorbi F; Donner D; Alongi P;
Ann Nucl Med; 2018 Jan; 32(1):7-15. PubMed ID: 28986764
[TBL] [Abstract][Full Text] [Related]
17. Thyroid Incidentaloma on 18F-fluorocholine PET/CT and 68Ga-PSMA PET/CT Revealing a Medullary Thyroid Carcinoma.
Ciappuccini R; Edet-Sanson A; Saguet-Rysanek V; Gauthé M; Bardet S
Clin Nucl Med; 2019 Aug; 44(8):663-665. PubMed ID: 31274618
[TBL] [Abstract][Full Text] [Related]
18. Complementary roles of 18F-DOPA PET/CT and 18F-FDG PET/CT in medullary thyroid cancer.
Kauhanen S; Schalin-Jäntti C; Seppänen M; Kajander S; Virtanen S; Schildt J; Lisinen I; Ahonen A; Heiskanen I; Väisänen M; Arola J; Korsoff P; Ebeling T; Sane T; Minn H; Välimäki MJ; Nuutila P
J Nucl Med; 2011 Dec; 52(12):1855-63. PubMed ID: 22052128
[TBL] [Abstract][Full Text] [Related]
19. Clinical value of 18-fluorine-fluorodihydroxyphenylalanine positron emission tomography/computed tomography in the follow-up of medullary thyroid carcinoma.
Luster M; Karges W; Zeich K; Pauls S; Verburg FA; Dralle H; Glatting G; Buck AK; Solbach C; Neumaier B; Reske SN; Mottaghy FM
Thyroid; 2010 May; 20(5):527-33. PubMed ID: 20450432
[TBL] [Abstract][Full Text] [Related]
20. The value of 18F-DOPA PET/CT in patients with medullary thyroid carcinoma and increased calcitonin values.
Golubić AT; Pasini Nemir E; Žuvić M; Mutvar A; Kusačić Kuna S; Despot M; Samardžić T; Huić D
Nucl Med Commun; 2017 Jul; 38(7):636-641. PubMed ID: 28562377
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
